BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 16729968)

  • 1. Metabolites of ginsenosides as novel BCRP inhibitors.
    Jin J; Shahi S; Kang HK; van Veen HW; Fan TP
    Biochem Biophys Res Commun; 2006 Jul; 345(4):1308-14. PubMed ID: 16729968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of indomethacin and dexamethasone effects on BCRP-mediated drug resistance in MCF-7 parental and resistant cell lines.
    Elahian F; Kalalinia F; Behravan J
    Drug Chem Toxicol; 2010 Apr; 33(2):113-9. PubMed ID: 20307139
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-expression of cytokeratin 8 and breast cancer resistant protein indicates a multifactorial drug-resistant phenotype in human breast cancer cell line.
    Liu F; Fan D; Qi J; Zhu H; Zhou Y; Yang C; Zhu Z; Xiong D
    Life Sci; 2008 Sep; 83(13-14):496-501. PubMed ID: 18725232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Regulation mechanism of breast cancer resistance protein by toremifene to reverse BCRP-mediated multidrug resistance in breast cancer cells].
    Zhang YH; Li G; Yu J; Xu MS; Liu ZX
    Zhonghua Zhong Liu Za Zhi; 2011 Sep; 33(9):654-60. PubMed ID: 22340044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
    Sinha BK; Perera L; Cannon RE
    Biomed Pharmacother; 2019 Dec; 120():109468. PubMed ID: 31605952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TTFields alone and in combination with chemotherapeutic agents effectively reduce the viability of MDR cell sub-lines that over-express ABC transporters.
    Schneiderman RS; Shmueli E; Kirson ED; Palti Y
    BMC Cancer; 2010 May; 10():229. PubMed ID: 20492723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2).
    Ma MT; He M; Wang Y; Jiao XY; Zhao L; Bai XF; Yu ZJ; Wu HZ; Sun ML; Song ZG; Wei MJ
    Cancer Lett; 2013 Oct; 339(1):107-15. PubMed ID: 23879965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular expression and functional evidence of a drug efflux pump (BCRP) in human corneal epithelial cells.
    Karla PK; Earla R; Boddu SH; Johnston TP; Pal D; Mitra A
    Curr Eye Res; 2009 Jan; 34(1):1-9. PubMed ID: 19172464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flavonoids are inhibitors of breast cancer resistance protein (ABCG2)-mediated transport.
    Zhang S; Yang X; Morris ME
    Mol Pharmacol; 2004 May; 65(5):1208-16. PubMed ID: 15102949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    Shiozawa K; Oka M; Soda H; Yoshikawa M; Ikegami Y; Tsurutani J; Nakatomi K; Nakamura Y; Doi S; Kitazaki T; Mizuta Y; Murase K; Yoshida H; Ross DD; Kohno S
    Int J Cancer; 2004 Jan; 108(1):146-51. PubMed ID: 14618629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
    Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
    Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
    Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
    Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (20S)-Protopanaxadiol Ginsenosides Induced Cytotoxicity via Blockade of Autophagic Flux in HGC-27 Cells.
    Han Q; Han L; Tie F; Wang Z; Ma C; Li J; Wang H; Li G
    Chem Biodivers; 2020 Jul; 17(7):e2000187. PubMed ID: 32384197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transcriptional modulation of BCRP gene to reverse multidrug resistance by toremifene in breast adenocarcinoma cells.
    Zhang Y; Wang H; Wei L; Li G; Yu J; Gao Y; Gao P; Zhang X; Wei F; Yin D; Zhou G
    Breast Cancer Res Treat; 2010 Oct; 123(3):679-89. PubMed ID: 19967559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucosamine attenuates drug resistance in Mitoxantrone-resistance breast cancer cells.
    Valinezhad Sani F; Palizban A; Mosaffa F; Jamialahmadi K
    J Pharm Pharmacol; 2021 Jun; 73(7):922-927. PubMed ID: 33885909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.